Dr. Jeanmarie Guenot earned an MBA from the Wharton School at the University of Pennsylvania and a Ph.D. from the University of California, San Francisco.

She is the President and CEO of Amphivena Therapeutics, Inc. The company develops innovative bifunctional antibody therapies used in treating hematological malignancies. She has more than 20 years of experience in the biotechnology and pharmaceutical industry.

Her experience includes all stages of venture capital, project and alliance management, business development, commercial and corporate development and pharmaceutical research and development for private and public companies. Her interest lies in building or rebuilding companies.

Before becoming the President and CEO of Amphivena Therapeutics, Dr. Guenot built SKS Ocular. It was a start-up ophthalmic company incubator that focused on ocular inflammation, macular degeneration, glaucoma therapeutics, and technology for sustained ocular drug delivery.

Jeanmarie Guenot served as a business adviser for Hoffmann-La Roche in Shanghai and Basel. In 2003, she joined PDL BioPharma. In 2005 she became the Vice President of Corporate and Business Development. There, she led alliance management, acquisitions and mergers, and licensing for the company’s commercial products and research and development portfolios.

Awards received by Dr. Guenot include a 2005 BioBusiness Network’s Innovative Bio-Partnering Award. In 2006, she received the Licensing Executives Society’s Deal of Distinction Award.

Dr. Guenot was the leader and negotiator for the strategic collaboration for the co-development and co-commercialization of Biogen Idec-PDL 50:50. The collaboration involved three autoimmune disease and Phase 2 cancer drug candidates. Part of the eight million dollar transaction included a one million dollar equity investment in a therapeutic candidate and PDL, split between Hoffmann-La Roche and Biogen Idec/PDL. She licensed the oncology drug ophthalmic indication to Ophthotech.

Areas in her portfolio, and alliance and management experience include ophthalmic and neurology diseases, autoimmune diseases, cardiovascular diseases, and oncology. Dr. Guenot began her career working for Atlas Venture. She provided financing for early stage life science companies. Her work there included building life science companies and managing venture capital investments.

Jeanmarie’s scientific career began when she worked for Hoffmann-La Roche in preclinical research and development. As a principal scientist, her work entailed discovering and developing drugs for oncology, autoimmune diseases, inflammation, and metabolic diseases. She trained in medicinal and physical chemistry. Her focus was on semi-empirical and quantum mechanical methods for drug design, nuclear magnetic resonance and X-ray refinement, and protein structure prediction.

In addition to her affiliation with Amphivena Therapeutics, Dr. Guenot began working with Harpoon Therapeutics, Inc. in August of 2014. In 2016, Dr. Guenot was one of the co-founders of Maverick Therapeutics. It is a private start-up biotechnology company. The company is a spin-off of Harpoon Therapeutics.

Dr. Guenot believes the T-cell engagement format of Maverick has the potential of eliminating inherent toxicity challenges in using T-cell radiation therapy due to target antigen expression on normal tissue. Maverick’s design of therapeutic antibodies are inactive upon administration, but active in the microenvironment of a tumor.